Showing 7121-7130 of 7438 results for "".
- La Roche-Posay and WDS Expand Sun Protection Campaignhttps://practicaldermatology.com/news/20130320-la_roche-posay_and_wds_expand_sun_protection_campaign/2459583/La Roche-Posay and the Women's Dermatologic Society (WDS) are taking their Time Out, Protect Your Skin (TOPS) initiative national. Launching this year in five public and private schools across the country, the TOPS program will increase awareness about sun protection and instill good skin health hab
- District Court Judge Blocks Marketing and Sales of RevitaLashhttps://practicaldermatology.com/news/20130320-district_court_judge_blocks_marketing_and_sales_of_revitalash/2459584/A district court judge recently prohibited Athena Cosmetics, Inc. from marketing or selling its RevitaLash Advanced Eyelash Conditioner in the United States. The ruling came as part of a civil lawsuit brought by Allergan Inc., maker of Latisse, in which the company claimed unfair competition in the
- Survey: Scars and Stretch Marks Significantly Impact Women's Confidencehttps://practicaldermatology.com/news/20130318-survey_scarsstretch_marks_have_significant_negative_impact_womens_confidence/2459586/A new survey reveals that men and women have complex and often differing feelings about how their skin Imperfections impact their appearance and confidence. In the Mederma® Wear Your Skin Proudly™ survey, 34 percent of women reported that the appearance of scar(s) and/or stretch marks would make the
- SkinMedica Unveils Hydroquinone-Free Skin Brightening Complexhttps://practicaldermatology.com/news/20130314-skinmedica_unveils_hydroquinone-free_skin_brightening_complex/2459588/SkinMedica introduced its new skin brightening product, SkinMedica Lytera™ Skin Brightening Complex, a hydroquinone-free product that reduces the appearance of skin discoloration and dark spots. Featuring a proprietary blend of ingredients, SkinMedica Lytera™ Skin Brightening Complex works to bright
- NeoStrata Introduces Line Lift Duohttps://practicaldermatology.com/news/20130314-neostrata_introduces_line_lift_duo/2459589/NeoStrata Company, Inc. launched the SKIN ACTIVE Line Lift featuring Aminofil™, a novel tyrosine amino acid derivative (N-Acetyl Tyrosinamide) that delivers a rapid volumizing effect in the deep skin matrix to visibly reduce deep facial lines and wrinkles. Applied together twice daily, the SKIN ACTI
- Dermablend Launches Concealer and Highlighter for Clearer Complexionhttps://practicaldermatology.com/news/20130314-dermablend_launches_concealer_and_highlighter_for_clearer_complexion/2459590/Dermablend's new Quick-Fix Illuminator is a multi-purpose concealer and highlighter that can conceal, smooth, illuminate, brighten, highlight and sculpt the face for an improved complexion. According to the company, the Quick-Fix Illuminator is safe for even the most sensitive skin diminishes dark c
- PhotoMedex Launches Three New Neova Productshttps://practicaldermatology.com/news/20130311-photomedex_launches_three_new_neova_products/2459594/Three new Neova products are now available from PhotoMedex. The first is Serious Clarity 4X, an advanced serum with four highly effective brighteners that reverse the appearances of dark spots and skin discolorations. Also available is Illuminating Eye Therapy 4.0, which is designed to combat dark c
- Investigational Injectable Found Safe, Effective for Submental Fathttps://practicaldermatology.com/news/20130311-investigational_injectable_found_safe_effective_for_submental_fat/2459596/An investigational injectable drug for the reduction of submental fat called ATX-101 from Kythera Biopharmaceuticals was found both safe and effective in new data presented at the AAD Meeting in Miami. In the open-label Phase IIIb study, interim results three months after the last ATX-101 treatment
- Naftifine Gel Found Effective for Moccasin-Type Tinea Pedishttps://practicaldermatology.com/news/20130307-naftifine_gel_found_effective_for_moccasin-type_tinea_pedis/2459600/New data has found that the topical antifungal agent naftifine hydrochloride gel 2% (Merz North America) is both efficacious and tolerable in the treatment for interdigital-type and moccasin-type Tinea pedis. In a poster presented at the AAD Annual Meeting in Miami, the authored sounds that naftifin
- Omalizumab Shown to Significantly Improve Chronic Idiopathic Urticaria Symptomshttps://practicaldermatology.com/news/20130227-omalizumab_shown_to_significantly_improve_chronic_idiopathic_urticaria_symptoms/2459605/Results from the recent ASTERIA II trial showed that the biologic agent omalizumab (Novartis) may be effective for patients with moderate to severe chronic idiopathic urticaria (CIU), referred to as chronic spontaneous urticaria (CSU) outside the United States, who remained symptomatic despite treat